These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8957673)

  • 41. Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region.
    Melnychuk L; Ajamian L; Jean-Pierre P; Liang J; Gheorghe R; Wainberg MA; Zaharatos GJ
    Vaccine; 2017 May; 35(20):2736-2744. PubMed ID: 28392143
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic engineering and characterization of Cowpea mosaic virus empty virus-like particles.
    Sainsbury F; Saxena P; Aljabali AA; Saunders K; Evans DJ; Lomonossoff GP
    Methods Mol Biol; 2014; 1108():139-53. PubMed ID: 24243247
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.
    Arnold GF; Velasco PK; Holmes AK; Wrin T; Geisler SC; Phung P; Tian Y; Resnick DA; Ma X; Mariano TM; Petropoulos CJ; Taylor JW; Katinger H; Arnold E
    J Virol; 2009 May; 83(10):5087-100. PubMed ID: 19279101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cowpea mosaic virus-based chimaeras. Effects of inserted peptides on the phenotype, host range, and transmissibility of the modified viruses.
    Porta C; Spall VE; Findlay KC; Gergerich RC; Farrance CE; Lomonossoff GP
    Virology; 2003 May; 310(1):50-63. PubMed ID: 12788630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.
    Brennan FR; Bellaby T; Helliwell SM; Jones TD; Kamstrup S; Dalsgaard K; Flock JI; Hamilton WD
    J Virol; 1999 Feb; 73(2):930-8. PubMed ID: 9882293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence for participation of RNA 1-encoded elicitor in Cowpea mosaic virus-mediated concurrent protection.
    Bruening G; Buzayan JM; Ferreiro C; Lim W
    Virology; 2000 Jan; 266(2):299-309. PubMed ID: 10639316
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein.
    Lin G; Nara PL
    Curr HIV Res; 2007 Nov; 5(6):514-41. PubMed ID: 18045109
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants.
    Gu R; Stagnar C; Zaichenko L; Ramsingh AI
    Vaccine; 2012 May; 30(24):3666-74. PubMed ID: 22464964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1.
    Li H; Liu ZQ; Ding J; Chen YH
    Immunol Lett; 2002 Nov; 84(2):153-7. PubMed ID: 12270553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
    Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
    Front Immunol; 2020; 11():719. PubMed ID: 32411138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1.
    Kalyan NK; Lee SG; Wilhelm J; Pisano MR; Hum WT; Hsiao CL; Davis AR; Eichberg JW; Robert-Guroff M; Hung PP
    Vaccine; 1994 Jun; 12(8):753-60. PubMed ID: 7522383
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plant expression systems for the production of vaccines.
    Ma JK; Vine ND
    Curr Top Microbiol Immunol; 1999; 236():275-92. PubMed ID: 9893365
    [No Abstract]   [Full Text] [Related]  

  • 53. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
    Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL
    Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR.
    Matoba N; Kajiura H; Cherni I; Doran JD; Bomsel M; Fujiyama K; Mor TS
    Plant Biotechnol J; 2009 Feb; 7(2):129-45. PubMed ID: 19037902
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles.
    Haffar OK; Smithgall MD; Moran PA; Travis BM; Zarling JM; Hu SL
    Virology; 1991 Aug; 183(2):487-95. PubMed ID: 1906660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
    Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF
    EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41.
    Pastori C; Tudor D; Diomede L; Drillet AS; Jegerlehner A; Röhn TA; Bomsel M; Lopalco L
    Virology; 2012 Sep 15-30; 431(1-2):1-11. PubMed ID: 22658900
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.
    Liu Z; Chen YH
    J Immunol Methods; 2004 Feb; 285(1):93-7. PubMed ID: 14871538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus.
    McLain L; Durrani Z; Wisniewski LA; Porta C; Lomonossoff GP; Dimmock NJ
    Vaccine; 1996 Jun; 14(8):799-810. PubMed ID: 8817828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.